TG Therapeutics
TGTX | NASDAQ
$62.76
-$1.75 (-2.71%)
At close: Nov 16, 2026, 4:00 PM ET
$62.74
-$0.02 (-0.03%)
After-hours:
Nov 16, 2026, 7:30 PM ET
TG Therapeutics Company Profile
Company profile explainedCompany Profile
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Key Executives
| Name | Position |
|---|---|
| Michael S. Weiss | Chairman, Chief Executive Officer & President |
| Sean A. Power | Chief Financial Officer, Corporate Secretary & Treasurer |
| Adam Waldman | Chief Commercialization Officer |
| Jenna Bosco | Senior Vice President of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 14, 2026 | 4 | Filing |
| Aug 07, 2026 | 4 | Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 03, 2026 | 8-K | Current Report |
| Jun 15, 2026 | 4 | Filing |
| Jun 15, 2026 | 4 | Filing |
| Jun 15, 2026 | 4 | Filing |
| Jun 15, 2026 | 4 | Filing |
| Jun 15, 2026 | 4 | Filing |
TG Therapeutics
| Country | United States |
| IPO Date | May 3, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 399 |
| CEO | Michael S. Weiss |
Contact Details
3020 Carrington Mill Blvd. Morrisville,
New York 27560 United States
Stock Details
| Ticker Symbol | TGTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001001316 |
| CUSIP Number | 88322Q108 |
| ISIN Number | US88322Q1085 |
| SIC Code | 2834 |
Recent News
- 2 days ago / fool.comTG Therapeutics: 3 Key Takeaways for Long-Term Investors
- 6 days ago / zacks.comTGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up
- 7 days ago / seekingalpha.comTG Therapeutics, Inc. (TGTX) Q3 2026 Earnings Call Transcript
- 8 days ago / marketbeat.comWhat TG Therapeutics (TGTX) Said on Its Q3 Earnings Call
- 8 days ago / zacks.comTG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to Say
- 8 days ago / zacks.comTG Therapeutics (TGTX) Beats Q3 Earnings and Revenue Estimates
- 8 days ago / businesswire.comTG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
- 15 days ago / businesswire.comTG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
- 22 days ago / zacks.comTG Therapeutics (TGTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- 1 month ago / zacks.comTGTX Stock Rises 60% in 6 Months: Here's What You Should Know
Add to Watchlist
Select watchlists to add or remove TGTX